Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology medicines both globally and in the US. Fougera has strong dermatology development and manufacturing expertise, particularly in the area of semi-solid forms such as creams and ointments, as well as a well-known branded business, PharmaDerm. Sandoz plans to expand Fougera's broad dermatology portfolio to new markets around the world. Fougera will be integrated into Sandoz's US business based in Princeton, NJ, but will continue to exist as a separate legal entity. Fougera, based in Melville, NY, will be the new center of generic dermatology development and manufacturing within the global Sandoz network.